01 Standardized Connector Platforms Improve Single-Use System Compatibility The growing complexity of biopharmaceutical manufacturing is driving the adoption of standardized connector platforms in the single-use assemblies market. Manufacturers are transitioning from facility-specific assembly designs to interoperable single-use systems with standardized connectors and tubing interfaces across production lines. For example, Cytiva has expanded its standardized single-use connection technologies to improve compatibility across upstream and downstream bioprocessing operations.
02 Gamma-Stable High-Performance Polymers Enhance Assembly Durability The increasing demand for robust sterilized bioprocessing components is accelerating the use of advanced gamma-stable polymer materials in single-use assemblies. This shift is extending component reliability while supporting demanding biologics manufacturing processes. For example, Entegris develops high-performance polymer solutions for single-use bioprocessing applications that withstand gamma sterilization while maintaining product integrity.
01 The single-use assemblies market forecasts sustained investment as biopharmaceutical manufacturers expand biologics, cell and gene therapy, and vaccine production capacity.
02 Key Investment and Funding Activities in Single-Use Assemblies Market, 2025–2026 Company Funding/Investment (USD) Details Thermo Fisher Scientific USD 2,000 Million In June 2026, Thermo Fisher Scientific announced a USD 2 billion investment to expand its U.S. manufacturing operations, including facilities supporting bioprocessing technologies and single-use production systems for biologics manufacturing. Thermo Fisher Scientific USD 4,100 Million In February 2025, Thermo Fisher Scientific announced the acquisition of Solventum's Purification & Filtration business for USD 4.1 billion, significantly expanding its filtration and bioprocessing portfolio, including technologies used in single-use bioprocess manufacturing.
01 The single-use assemblies market is highly exposed to supply chain disruptions due to its dependence on specialized polymers, bioprocessing components, sterile filtration systems, tubing, connectors, and single-use bags sourced through globally integrated supply networks. Shortages of medical-grade raw materials, transportation delays, and stringent quality and regulatory requirements have increased lead times, constrained production capacity, and encouraged manufacturers to regionalize production, qualify multiple suppliers, and maintain higher safety inventories. The market is expected to experience a capacity-constrained recovery, as demand from biologics, cell and gene therapy, and vaccine manufacturing continues to outpace the expansion of specialized production capacity and the availability of high-quality raw materials.
01 Biomanufacturing Agility and Capacity Optimization Accelerate Single-Use Assemblies Market Demand Biopharmaceutical companies are increasingly designing facilities that can manufacture multiple products without dedicating production lines to a single therapy. This manufacturing strategy increases demand for single-use assemblies because they enable rapid process changeovers while minimizing downtime between production batches. For example, Lonza and FUJIFILM Diosynth Biotechnologies utilize flexible single-use manufacturing platforms to accommodate multiple customer programs within the same facility.The growing number of cell therapies, gene therapies, orphan drugs, and personalized biologics is shifting manufacturing from high-volume production toward smaller, specialized batches. This transition increases demand for single-use assemblies because they eliminate extensive cleaning validation and allow faster preparation between production campaigns. For instance, Sartorius and Cytiva continue expanding single-use solutions designed specifically for cell and gene therapy production.
01 Supplier Qualification Complexity and Dependence on Specialized Polymer Supply Chains Restrain Market Expansion Single-use assemblies consist of tubing, bags, connectors, filters, and manifolds that become part of validated pharmaceutical manufacturing processes. Even minor component modifications require manufacturers to repeat qualification studies, compatibility testing, and regulatory documentation before implementation. This lengthy validation process slows supplier replacement and delays adoption of newer technologies.Manufacturers rely on highly specialized medical-grade polymers that must meet stringent biocompatibility and regulatory requirements before entering pharmaceutical production. Limited availability of qualified raw materials and approved component suppliers restricts production flexibility and increases procurement risks. This dependence slows market expansion during periods of supply chain disruption.
01 Platform Manufacturing and Regional Biomanufacturing Expansion Create Future Growth Opportunities Biopharmaceutical companies increasingly standardize manufacturing processes across multiple biologic products, creating opportunities for single-use assembly manufacturers, CDMOs, engineering firms, and equipment suppliers to develop modular, platform-compatible disposable systems. Standardized assemblies simplify technology transfer while reducing engineering complexity across manufacturing sites. As platform manufacturing expands globally, demand for standardized single-use assemblies is expected to grow significantly. Companies such as Thermo Fisher Scientific, Merck KGaA, and Sartorius continue expanding standardized single-use bioprocess platforms.Governments and pharmaceutical companies are investing in domestic biologics manufacturing to strengthen healthcare resilience and reduce dependence on imported medicines, creating opportunities for single-use assembly manufacturers, local suppliers, CDMOs, and facility developers. Newly established manufacturing sites increasingly adopt disposable technologies because they reduce facility complexity and accelerate commercial operations. As regional biomanufacturing capacity expands across Asia Pacific, the Middle East, and Latin America, demand for single-use assemblies is expected to increase steadily. Companies including Cytiva and Danaher continue investing in regional manufacturing capabilities to support this transition.
01 Supply Chain Visibility and Lifecycle Sustainability Challenge Long-Term Market Growth Single-use assemblies contain multiple components sourced from different suppliers, making complete material traceability increasingly difficult as supply chains become more global. Maintaining documentation, quality consistency, and regulatory compliance across every component supplier requires continuous oversight and increases operational complexity. This directly affects production planning and supplier management for biopharmaceutical manufacturers.Healthcare manufacturers increasingly face pressure to reduce plastic waste while maintaining the sterility, performance, and regulatory compliance of disposable bioprocess components. The development of sustainable disposal and recycling solutions without compromising product quality remains a significant challenge for the industry.
April 2026 Freudenberg Medical launched CleanAssure, an ISO Class 5 controlled cleanroom service for sterile single-use assemblies. The facility provides controlled washing, drying, and gamma sterilization for ready-to-use biopharma assemblies.
December 2025 Thermo Fisher Scientific opened a new Bioprocess Design Center in Hyderabad and expanded its facilities in Incheon and Singapore. The network provides advanced bioprocess technologies and process-development support relevant to single-use biomanufacturing workflows.